Judge Allows Experts in 67,500 Talc Cases
Special master approves expert testimony in 67,500 J&J talc lawsuits, clearing the path for federal trials in ovarian cancer cases.
A court-appointed special master has recommended allowing expert testimony in more than 67,500 federal lawsuits alleging Johnson & Johnson’s talc-based baby powder caused ovarian cancer, removing a major obstacle to trials.
The Ruling
Retired U.S. District Judge Freda Wolfson, serving as special master in the multidistrict litigation consolidated in New Jersey federal court, issued a 600-page ruling on January 20, 2026 finding that plaintiffs’ expert witnesses meet the scientific standards required by federal law.
The ruling addressed challenges Johnson & Johnson raised under the Daubert standard, which requires courts to evaluate whether expert testimony is based on reliable methodology before allowing it at trial.
What the Special Master Found
Judge Wolfson’s recommendation allows testimony from causation experts linking perineal talc use to ovarian cancer, from science and geology experts testifying that J&J talc contained trace or ultra-trace asbestos, and from testing methodology experts explaining that historical testing methods, when properly applied, could detect asbestos contamination.
Throughout her exhaustive review, Judge Wolfson emphasized that the issues raised by J&J are “issues for juries” to weigh, not grounds for excluding testimony.
Why This Matters
This ruling is significant for three reasons. It clears the path for federal bellwether trials in the District of New Jersey, with the first one expected later in 2026. It validates plaintiffs’ scientific evidence, after years of J&J claiming “junk science,” by having a federal judge find the methodology sound. And it aligns the federal MDL with multiple state court verdicts that have already found talc caused cancer.
A History of Legal Obstacles
Johnson & Johnson has fought to prevent these cases from reaching trial. The multidistrict litigation was created in the District of New Jersey in 2016. Between 2021 and 2025, J&J attempted three bankruptcy maneuvers to resolve the claims, all of which were rejected by the courts. New federal rules in 2024 strengthened courts’ role in vetting expert testimony, and in January 2026 the special master ruled that the plaintiffs’ expert testimony is admissible.
This is the second time Judge Wolfson reviewed the scientific evidence. She originally oversaw the MDL from 2016 until her retirement in 2023. In 2024, Judge Michael Shipp, who now oversees the litigation, requested a fresh review due to new federal rules and emerging scientific evidence.
Johnson & Johnson’s Response
Johnson & Johnson maintains its talc products are safe and do not cause cancer. The company has:
- Stopped selling talc-based baby powder in the U.S. (2020)
- Discontinued talc baby powder globally (2023)
- Switched to cornstarch-based products
- Contested all verdicts and continues to appeal
The company characterized the expert testimony as unreliable, but the special master disagreed.
What Happens Next
With expert testimony approved, the consolidated federal cases can proceed toward trial. The special master’s recommendation now goes to Judge Michael Shipp, the presiding judge, for adoption. The parties will then select bellwether cases as representative trials, and the first federal trial is expected later in 2026.
Meanwhile, state court trials continue nationwide, with over $2.5 billion in verdicts awarded against J&J in 2025 alone.
Related Reading
Reader Q&A
Frequently Asked Questions
What is the Daubert standard?
The Daubert standard is a federal rule requiring courts to evaluate whether expert testimony is based on reliable scientific methodology before allowing it at trial. Judges act as gatekeepers, assessing factors like peer review, testing, error rates, and general acceptance in the scientific community. In the J&J talc litigation, the special master applied this standard and found that plaintiffs’ experts met the threshold.
What did Judge Wolfson's report recommend?
Her 600-plus page report recommended allowing plaintiffs’ expert witnesses to testify that J&J talc caused ovarian cancer, finding their methodologies met scientific standards. The report concluded there is a “positive, statistically significant association” between genital talc use and ovarian cancer, supported by studies published both before and after 2020. She also recommended excluding some testimony about heavy metals, fragrance chemicals, and talc migration through inhalation.
How many lawsuits does this affect?
The ruling affects more than 67,500 federal lawsuits consolidated in the New Jersey multidistrict litigation. State court cases, which have already produced billions of dollars in verdicts, proceed on separate tracks and are not directly governed by this recommendation.
When will federal trials begin?
The first bellwether trial is expected later in 2026. Before that can happen, Judge Michael Shipp must formally adopt the special master’s recommendation. After that, representative cases will be selected and scheduled for trial.
How much is the talcum powder lawsuit going to payout?
Talcum powder lawsuits linked to mesothelioma in people with exposure to asbestos-contaminated products have resulted in varied payouts, with averages for mesothelioma claims reported between $1 million and $1.4 million according to Mealey’s Asbestos Litigation Report. Legal industry estimates place general talc settlements lower, around $500,000 per plaintiff, though individual verdicts range from $8 million to over $966 million before reductions. Johnson & Johnson has proposed multi-billion-dollar funds, such as $6.48 billion in 2024, but final per-person amounts depend on case details like diagnosis severity and usage duration, with many resolved confidentially.
Is the talcum powder lawsuit real?
Yes, talcum powder lawsuits against Johnson & Johnson are real and ongoing, with over 90,000 claims filed alleging asbestos contamination in talc-based products like Baby Powder caused ovarian cancer and mesothelioma in people with long-term exposure. As of April 2026, the multidistrict litigation (MDL No. 2738) in New Jersey includes 67,376 cases, marking it as the largest MDL in the U.S., while state courts handle additional filings. Juries have awarded billions in verdicts, such as $8 million to a Massachusetts woman with mesothelioma in 2025 and $40 million to two California women with ovarian cancer in December 2025, though many have been reduced on appeal. Johnson & Johnson maintains its products were safe and has ceased U.S. sales of talc-based Baby Powder, replacing it with cornstarch. Litigation continues without resolution via bankruptcy attempts, dismissed as recently as 2025.
What is the average payout for Johnson & Johnson?
Johnson & Johnson talcum powder lawsuit settlements and verdicts show wide variation, with no fixed average payout across all claims. Legal industry estimates for talcum powder cases range from $100,000 to over $1 million per person, while mesothelioma-specific claims average $1 million to $1.4 million. Proposed settlements, such as the $8.9 billion offer in 2023 for thousands of claimants or $8.2 billion in 2024, project per-claimant payouts around $330,000 to $500,000 after division among plaintiffs. Individual verdicts include $1.5 million for a mesothelioma case in 2018 and $16 million compensatory damages upheld in 2026. Payouts depend on case details like injury type and asbestos exposure evidence.
How long could a talc lawsuit take to resolve?
Talcum powder lawsuits typically take several months to several years to resolve, depending on case complexity and whether the claim is part of a multidistrict litigation (MDL) or filed individually. Individual lawsuits filed in state court may resolve faster, sometimes within a few months through settlement negotiations, while MDL cases generally take longer due to the consolidation and bellwether trial process. According to trial lawyers, complex talcum powder cases can take three to seven years to settle. Once a settlement is reached, people with mesothelioma or ovarian cancer may receive payment within one to two months, though timing depends on fund distribution processes and claim volume.